Galenea Signs Collaboration And License Agreement With Otsuka Pharmaceutical Co., Ltd.
10/19/2005 5:12:44 PM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 16, 2005--On January 8, 2005, Galenea Corp. signed a research and development collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. to discover novel pharmaceuticals for the treatment of central nervous system (CNS) diseases, including schizophrenia and bipolar disorder. The parties' collaboration includes an equity investment in Galenea by Otsuka Pharmaceutical.
comments powered by